Galcanezumab (Emgality) for Migraine and Cluster Headaches
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
---|---|
Enthalten in: |
American family physician - 101(2020), 8 vom: 15. Apr., Seite 502-503 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cheung, Jennifer Ren-Si [VerfasserIn] |
---|
Themen: |
55KHL3P693 |
---|
Anmerkungen: |
Date Completed 14.06.2022 Date Revised 14.06.2022 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM30878765X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM30878765X | ||
003 | DE-627 | ||
005 | 20231225132507.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n1029.xml |
035 | |a (DE-627)NLM30878765X | ||
035 | |a (NLM)32293845 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cheung, Jennifer Ren-Si |e verfasserin |4 aut | |
245 | 1 | 0 | |a Galcanezumab (Emgality) for Migraine and Cluster Headaches |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.06.2022 | ||
500 | |a Date Revised 14.06.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a galcanezumab |2 NLM | |
650 | 7 | |a 55KHL3P693 |2 NLM | |
650 | 7 | |a erenumab |2 NLM | |
650 | 7 | |a I5I8VB78VT |2 NLM | |
700 | 1 | |a Erlich, Deborah R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t American family physician |d 1970 |g 101(2020), 8 vom: 15. Apr., Seite 502-503 |w (DE-627)NLM000077771 |x 1532-0650 |7 nnns |
773 | 1 | 8 | |g volume:101 |g year:2020 |g number:8 |g day:15 |g month:04 |g pages:502-503 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 101 |j 2020 |e 8 |b 15 |c 04 |h 502-503 |